Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1, but paradoxically inhibit its translation: A potential mechanism of cell cycle dysregulation

Carcinogenesis

Volumn 24, Issue 6, 2003, Pages 1045-1058

  Le, Nghia T V ^a,b   Richardson, Des R ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHALDEHYDE ISONICOTINOYL HYDRAZONE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DACTINOMYCIN; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; HYDRAZONE DERIVATIVE; IRON; IRON CHELATING AGENT; MESSENGER RNA; PROTEIN P21; PROTEIN P53; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TIME; IRON CHELATION; IRON DEPLETION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; STATISTICAL ANALYSIS; TUMOR CELL;

CELL CYCLE; CELLS, CULTURED; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE ENDOPEPTIDASES; DACTINOMYCIN; DEFEROXAMINE; DNA DAMAGE; GENE EXPRESSION REGULATION; HUMANS; IRON CHELATING AGENTS; ISONIAZID; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; RECEPTORS, TRANSFERRIN; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038687772     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg042     Document Type: Review

References (83)

1. Hershko,C. (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clin. Haematol., 7, 965-1000.
2. 1 phase of the cell cycle. Cancer Res., 53, 3968-3975.
3. Richardson,D.R. (1997) Iron chelators as effective anti-proliferative agents. Can. J. Physiol. Pharmacol., 75, 1164-1180.
4. Thelander,L. and Reichard,P. (1979) Reduction of ribonucleotides. Annu. Rev. Biochem., 48, 133-158.
5. Alcantara,O., Kalidas,M., Baltathakis,I. and Boldt,D.H. (2001) Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. Exp. Hematol., 29, 1060-1069.
6. Darnell,G. and Richardson,D.R. (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 94, 781-792.
7. Gao,J. and Richardson,D.R. (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 98, 842-850.
8. Kulp,K.S., Green,S.L. and Vulliet,P.R. (1996) Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res., 229, 60-68.
9. Richardson,D.R. and Milnes,K. (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
10. Simonart,T., Degraef,C., Andrei,G., Mosselmans,R., Hermans,P., Van Vooren,J.P., Noel,J.C., Boelaert,J.R., Snoeck,R. and Heenen,M. (2000) Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol., 115, 893-900.
11. Sherr,C.J. (1994) G1 phase progression: cycling on cue. Cell, 79, 551-555.
12. Terada,N., Lucas,J.J. and Gelfand,E.W. (1991) Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53 during cell cycle progression of normal human T cells. J. Immunol., 147, 698-704.
13. Vidal,A. and Koff,A. (2000) Cell-cycle inhibitors: three families united by a common cause. Gene, 247, 1-15.
14. El-Deiry,W.S., Tokino,T., Velculescu,V.E., Levy,D.B., Parsons,R., Trent,J.M., Lin,D., Mercer,W.E., Kinzler,K.W. and Vogelstein,B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
15. Harper,J.W., Adami,G.R., Wei,N., Keyomarsi,K. and Elledge,S.J. (1993) The p21 Cdk-interacting protein Cip is a potent inhibitor of G1 cyclin-dependent kinase. Cell, 75, 805-816.
16. Xiong,Y., Hannon,G.J., Zhang,H., Casso,D., Kobayashi,R. and Beach,D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
17. Gartel,A.L. and Tyner,A.L. (1999) Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp. Cell Res., 246, 280-289.
18. An,W.G., Kanekal,M., Simon,M.C., Maltepe,E., Blagosklonny,M.V. and Neckers,L.M. (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature, 392, 405-408.
19. Fukuchi,K., Tomoyasu,S., Watanabe,H., Tsuruoka,N. and Gomi,K. (1997) G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochim. Biophys. Acta, 1357, 297-305.
20. Green,D.A., Antholine,W.E., Wong,S.J., Richardson,D.R. and Chitambar,C.R. (2001) Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Clin. Cancer Res., 7, 3574-3579.
21. Suzuki,A., Tsutomi,Y., Yamamoto,N., Shibutani,T. and Akahane,K. (1999) Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death. Mal. Cell. Biol., 19, 3842-3847.
22. Luo,Y., Hurwitz,J. and Massague,J. (1995) Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature, 375, 159-161.
23. Waga,S., Hannon,G.J., Beach,D. and Stillman,B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578.
24. Delavaine,L. and La Thangue,N.B. (1999) Control of E2F activity by p21Waf1/Cip1. Oncogene, 18, 5381-5392.
25. Kitaura,H., Shinshi,M., Uchikoshi,Y., Ono,T., Iguchi-Ariga,S.M. and Ariga,H. (2000) Reciprocal regulation via protein-protein interaction between c-Myc and p21 (cip1/waf1/sdi1) in DNA replication and transcription. J. Biol. Chem., 275, 10477-10483.
26. Alt,J.R., Gladden,A.B. and Diehl,J.A. (2002) p21Cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J. Biol. Chem., 277, 8517-8523.
27. LaBaer,J., Garrett,M.D., Stevenson,L.F., Slingerland,J.M., Sandhu,C., Chou,H.S., Fattaey,A. and Harlow,E. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11, 847-862.
28. Blagosklonny,M.V., Wu,G.S., Omura,S. and El-Deiry,W.S. (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227, 564-569.
29. Torti,S.V., Torti,F.M., Whitman,S.P., Brechbiel,M.W., Park,G. and Planalp,R.P. (1998) Tumor cell cytotoxicity of a novel metal chelator. Blood, 92, 1384-1389.
30. Rakba,N., Loyer,P., Gilot,D., Delcros,J.G., Glaise,D., Baret,P., Pierre,J.L., Brissot,P. and Lescoat,G. (2000) Anti-proliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis, 21, 943-951.
31. Richardson,D.R., Tran,E.H. and Ponka,P. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86, 4296-4306.
32. Richardson,D.R., Hefter,G.T., May,P.M., Webb,J. and Baker,E. (1989) Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Metals, 2, 161-167
33. Vitolo,L.M.W., Hefter,G.T., Clare,B.W. and Webb,J. (1990) Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(II) and iron(II). Inorg. Chim. Acta, 170, 171-176.
34. Richardson,D.R. and Bernhardt,P. (1999) Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-proliferative activity. J. Biol. Inorg. Chem., 4, 266-273.
35. Becker,E. and Richardson,D.R. (1999) Development of novel aroylhydrazone ligands for iron chelation therapy: the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues. J. Lab. Clin. Med., 134, 510-521.
36. Chang,L.C., Sheu,H.M., Huang,Y.S., Tsai,T.R. and Kuo,K.W. (1999) A novel function of the nucleotide excision repair of UV and cisplatin-induced DNA damage in human cells. Biochem. Pharmacol., 58, 49-57.
37. Frolich,J.J., Schneller,F.R. and Zahn,R.K. (1999) The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation. Clin. Chem. Lab. Med., 37, 403-408.
38. Robles,S.J. and Adami,G.R. (1998) Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene, 16, 1113-1123.
39. Richardson,D.R. and Baker,E. (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta, 1053, 1-12.
40. Richardson,D.R. and Baker,E. (1992) Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem., 267, 13972-13979.
41. Karin,M. and Mintz,B. (1981) Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J. Biol. Chem., 256, 3245-3252.
42. Baker,E., Vitolo,M.L. and Webb,J. (1985) Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem. Pharmacol., 34, 3011-3017.
43. Lovejoy,D.B. and Richardson D.R. (2002) Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective anti-proliferative activity against tumor cells. Blood, 100, 666-676.
44. Hentze,M.W. and Kühn,L.C. (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc. Natl Acad. Sci. USA, 93, 8175-8182.
45. Ashcroft,M., Taya,Y. and Vousden,K.H. (2000) Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol., 20, 3224-3233.
46. Yazloviskaya,E.M., DeHaan,R.D. and Persons,D.L. (2001) Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem. Biophys. Res. Commun., 283, 732-737.
47. Waldman,T., Kinzler,K.W. and Vogelstein,B. (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55, 5187-5190.
48. Fritsche,M., Haessler,C. and Brandner,G. (1993) Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA damaging agents. Oncogene, 8, 307-318.
49. Wetzel,C.C. and Berberich,S.J. (1998) DNA binding activities of p53 protein following cisplatin damage of ovarian cells. Oncol. Res., 10, 151-161.
50. Sheaff,R.J., Singer,J.D., Swanger,J., Smitherman,M., Roberts,J.M. and Clurman,B.E. (2000) Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell, 5, 403-410.
51. An,W.G., Hwang,S.G., Trepel,J.B. and Blagosklonny,M.V. (2000) Protease inhibitor-induced apoptosis accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition. Leukemia, 14, 1276-1283.
52. Maki,C.G. and Howley,P.M. (1997) Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol., 17, 355-363.
53. Craiu,A., Gaczynska,M., Akopian,T., Gramm,C.F., Fenteany,G., Goldberg,A.L. and Rock,K.L. (1997) Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome, beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem., 16, 13437-13445.
54. Banerjee,D. and Liefshitz,A. (2001) Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination. Anticancer Res., 21, 3941-3947.
55. Lloyd,J.B., Cable,H. and Rice-Evans,C. (1991) Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem. Pharmacol., 41, 1361-1363.
56. Cable,H. and Lloyd,J.B. (1999) Cellular uptake and release of two contrasting iron chelators. J. Pharmacol., 51, 131-134.
57. Öllinger,K. and Brunk,U.T. (1995) Cellular injury induced by oxidative stress is mediated through lysosomal damage. Free Radic. Biol. Med., 19, 565-574.
58. Hess,P.A., McKee,P.H., Menage,H.D., Dover,R. and Lane,D.P. (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8, 203-207.
59. Li,R., Hannon,G.J., Beach,D. and Stillman,B. (1996) Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr. Biol., 6, 189-199.
60. McDonald,E.R.,III, Wu,G.S., Waldman,T. and El-Deiry,W.S. (1996) Repair defect in p21 WAF1/CIP1-/- human cancer cells. Cancer Res., 56, 2250-2255.
61. Wu,L. and Levine,A.J. (1997) Differential regulation of the p21WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med., 3, 441-451
62. Goto,Y., Paterson,M. and Listowsky,I. (1983) Iron uptake and regulation of ferritin synthesis by hepatoma cells in hormone-supplemented serum-free medium. J. Biol. Chem., 258, 5248-5255.
63. Ponka,P., Schulman,H.M. and Wilczynska,A. (1982) Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim. Biophys. Acta, 718, 151-156.
64. Ponka,P. and Schulman,H.M. (1985) Acquisition of iron from transferrin regulates reticulocyte heme synthesis. J. Biol. Chem., 260, 14717-14721.
65. Wardrop,S.L., Watts,R. and Richardson,D.R. (2000) Nitrogen monoxide (NO) activates IRP-RNA binding by two possible mechanisms - an effect on the Fe-S cluster and iron release from cells. Biochemistry, 39, 2748-2758.
66. Abeysinghe,R.D., Greene,B.T., Haynes,R., Willingham,M.C., Turner,J., Planalp,R.P., Brechbiel,M.W., Torti,F.M. and Torti,S.V. (2001) p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis, 22, 1607-1614.
67. Donfrancesco,A., Deb,G., Dominici,C., Pileggi,D., Castello,M.A. and Helson,L. (1990) Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 50, 4929-4930.
68. Estrov,Z., Tawa,A., Wang,X.H., Dube,I.D., Sulh,H., Cohen,A., Gelfand,E.W. and Freedman,M.H. (1987) In vivo and in vitro effects of desferrioxamine in neonatal acute leukaemia. Blood, 69, 757-761.
69. Finch,R.A., Liu,M.-C., Grill,S.P., Rose,W.C., Loomis,R., Vasquez,K.M., Cheng,Y.-C. and Sartorelli,A.C. (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 59, 983-991.
70. Goubin,F. and Ducommun,B. (1995) Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Oncogene, 10, 2281-2287.
71. WAF1/CIP1-null human fibroblasts are deficient in nucleotide excision repair downstream of the recruitment of PCNA to DNA repair sites. Oncogene, 20, 563-570.
72. Cip1/Waf1 in monocytic differentiation. EMBO J., 18, 1223-1234.
73. cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biol., 3, 245-252.
74. Caraglia,M., Tagliaferri,P., Budillon,A. and Abbruzzese,A. (1999) Post-translational modifications of eukaryotic initiation factor-5A (elF-5A) as a new target for anti-cancer therapy. Adv. Exp. Med. Biol., 472, 187-198.
75. Marone,M., Scambia,G., Giannitelli,C., Ferrandina,G., Masciullova,V., Bellacosa,A., Benedetti-Panici,P. and Mancuso,S. (1998) Analysis of cyclin E and cdk2 in ovarian cancer: Gene amplification and RNA overexpression. Int. J. Cancer, 75, 34-39.
76. Nyholm,S., Mann,G.J., Johansson,A.G., Bergeron,R.J., Gräslund,A. and Thelander,L. (1993) Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem., 268, 26200-26205.
77. Deng,C., Zhang,P., Harper,J.W., Elledge,S.T. and Leder,P. (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684.
78. Yoon,G., Kim,H.-J., Yoon,Y.-S., Cho,H., Lim,L.K. and Lee,J.-H. (2002) Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor β1 (TGF-β1)-mediated p27Kip1 expression. Biochem. J., 366, 613-621.
79. Elliott,M.J., Stilwell,A., Dong,Y.B., Yang,H.L., Wong,S.L., Wrightson,W.R., Martin,R.C. and McMasters,K.M. (2002) C-terminal deletion mutant p21 (WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells. Cancer Gene Ther., 9, 453-463.
80. Javelaud,D. and Besancon,F. (2002) Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of Bax/Bcl-2 ratio. J. Biol. Chem., 277, 37949-37954.
81. Martinez,L.A., Yang,J., Vazquez,E.S., Rodriguez-Vargas Mdel,C., Olive,M., Hsieh,J.T., Logothetis,C.J. and Navone,N.M. (2002) p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis, 23, 1289-1296.
82. Waldman,T., Lengauer,C., Kinzler,K.W. and Vogelstein,B. (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381, 713-716.
83. Blatt,J. and Huntley,D. (1989) Enhancement of in vitro activity against neuroblastoma by doxorubicin and deferoxamine. J. Natl Cancer Inst., 81, 866-870.